Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report

Dermatol Ther. 2009 Jul-Aug;22(4):386-90. doi: 10.1111/j.1529-8019.2009.01251.x.

Abstract

Psoriasis vulgaris is a chronic dermatosis and is a widespread dematological disease. The most represented lesions are erythemato-squamous plaques with a tendency to cover large body areas with a great impairment of normal activities and a poor quality of life. Very often psoriasis is associated to other illnesses and the dermatologist has to be aware that comorbidities have to be taken in account for a successfull treatment of the disease. We report a case of a patient affected by severe psoriasis and HCV infection. He underwent a first treatment with etenarcept with good clinical results and no change of his viral load. When etenarcept became ineffective, he received efalizumab, with a good control of his dermatological condition and a reduction of the viral load.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Etanercept
  • Hepatitis C, Chronic / complications*
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunologic Factors / therapeutic use
  • Male
  • Psoriasis / complications
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Severity of Illness Index
  • Viral Load

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunologic Factors
  • Receptors, Tumor Necrosis Factor
  • Etanercept
  • efalizumab